Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megadose Vitamin C in Sepsis (CEMVIS)
NCT05194189Phase 2Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in sepsis and septic shock comparing Megadose vitamin C group with Placebo group (2 arms). Primary endpoint: 28-day all-cause mortality. Started Feb 2022; status: completed.
02
Drugs
ascorbic acid
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT05194189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194189.